Cargando…
Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopat...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801928/ https://www.ncbi.nlm.nih.gov/pubmed/35099664 http://dx.doi.org/10.1007/s10792-022-02240-6 |
_version_ | 1784642565085069312 |
---|---|
author | Mimouni, Michael Ouano, Dean |
author_facet | Mimouni, Michael Ouano, Dean |
author_sort | Mimouni, Michael |
collection | PubMed |
description | PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopathy. A 1.0 cc syringe was partially filled with MMC (0.4 mg/mL) and attached to a 33-gauge needle used to cannulate the vessels. The MMC (0.01–0.05 ml) was injected with enough retrograde hydrostatic force to fill efferent and afferent vessels. Follow-up ranged from 4 months to 1 year. RESULTS: Three eyes of three patients aged 59, 73 and 33 years were included. There were no intraoperative or postoperative complications associated with the MICE procedure. Patient 1 presented with progressive corneal NV and lipid keratopathy secondary to herpes zoster ophthalmicus (HZO) and a best-corrected spectacle visual acuity (BSCVA) of 20/100 Snellen. At one-year post-MICE, there was no recurrence (BSCVA was 20/20 Snellen). Patient 2 presented with idiopathic lipid keratopathy (BSCVA 20/50 Snellen). At four months post-MICE, there were no signs of recurrence (BSCVA 20/20 Snellen). Patient 3 presented with corneal NV and lipid keratopathy secondary to HZO (BSCVA 20/30 Snellen). At four months following two MICE treatments, resolution of the lipid keratopathy was noted (BSCVA 20/20 Snellen). CONCLUSIONS: Preliminary findings suggest that MICE may be an additional modality for treating progressive corneal NV with lipid keratopathy. Larger comparative studies with longer follow-up are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10792-022-02240-6. |
format | Online Article Text |
id | pubmed-8801928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-88019282022-01-31 Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization Mimouni, Michael Ouano, Dean Int Ophthalmol Original Paper PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopathy. A 1.0 cc syringe was partially filled with MMC (0.4 mg/mL) and attached to a 33-gauge needle used to cannulate the vessels. The MMC (0.01–0.05 ml) was injected with enough retrograde hydrostatic force to fill efferent and afferent vessels. Follow-up ranged from 4 months to 1 year. RESULTS: Three eyes of three patients aged 59, 73 and 33 years were included. There were no intraoperative or postoperative complications associated with the MICE procedure. Patient 1 presented with progressive corneal NV and lipid keratopathy secondary to herpes zoster ophthalmicus (HZO) and a best-corrected spectacle visual acuity (BSCVA) of 20/100 Snellen. At one-year post-MICE, there was no recurrence (BSCVA was 20/20 Snellen). Patient 2 presented with idiopathic lipid keratopathy (BSCVA 20/50 Snellen). At four months post-MICE, there were no signs of recurrence (BSCVA 20/20 Snellen). Patient 3 presented with corneal NV and lipid keratopathy secondary to HZO (BSCVA 20/30 Snellen). At four months following two MICE treatments, resolution of the lipid keratopathy was noted (BSCVA 20/20 Snellen). CONCLUSIONS: Preliminary findings suggest that MICE may be an additional modality for treating progressive corneal NV with lipid keratopathy. Larger comparative studies with longer follow-up are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10792-022-02240-6. Springer Netherlands 2022-01-31 2022 /pmc/articles/PMC8801928/ /pubmed/35099664 http://dx.doi.org/10.1007/s10792-022-02240-6 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Mimouni, Michael Ouano, Dean Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title | Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title_full | Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title_fullStr | Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title_full_unstemmed | Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title_short | Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization |
title_sort | initial outcomes of mitomycin intravascular chemoembolization (mice) for corneal neovascularization |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801928/ https://www.ncbi.nlm.nih.gov/pubmed/35099664 http://dx.doi.org/10.1007/s10792-022-02240-6 |
work_keys_str_mv | AT mimounimichael initialoutcomesofmitomycinintravascularchemoembolizationmiceforcornealneovascularization AT ouanodean initialoutcomesofmitomycinintravascularchemoembolizationmiceforcornealneovascularization |